＜＜Back

Next＞＞

Vol. 27　Suppl.1　1999

*All papers include English abstract

Acute intravenous toxicity study of amrubicin hydrochloride (SM-5887) in rats

Y.Misaki, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s7-35*

---

Single intravenous toxicity study of amrubicin hydrochloride (SM-5887) in dogs

A.Kohda, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s37-62*

---

Four-week intravenous toxicity study on amrubicin hydrochloride (SM-5887) in rats

H.Adachi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s63-89*

---

Ninety-day intravenous toxicity study on amrubicin hydrochloride (SM-5887) in rats followed by 90-day recovery study

M.Kiguchi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s91-110*

---

Four-week intravenous toxicity study on amrubicin hydrochloride (SM-5887) in dogs

A.Kohda, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s111-219*

---

Five-day intravenous comparative toxicity study on amrubicin hydrochloride (SM-5887) and doxorubicin hydrochloride (DXR) in male rats

H.Adachi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s221-44*

---

A repeated dose toxicity study of amrubicin hydrochloride (SM-5887) administered intravesically to beagle dogs for 2 weeks followed by a 3 week recovery period

H.Sameshima, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s245-306*

---

Six-month intravenous toxicity study of amrubicin hydrochloride (SM-5887) in rats followed by 6-month recovery study

H.Shigeno, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s307-32*

---

Six-month intravenous toxicity study of amrubicin hydrochloride (SM-5887) in beagle dogs followed by 6-month recovery study

H.Shigeno, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s333-421*

---

Reproductive and developmental toxicity studies of amrubicin hydrochloride (SM-5887) (1)
－Fertility study in rats－

T.Furuhashi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s423-38*

---

Reproductive and developmental toxicity studies of amrubicin hydrochloride (SM-5887) (2)
－Teratogenicity study in rats－

T.Furuhashi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s439-460*

---

Reproductive and developmental toxicity studies of amrubicin hydrochloride (SM-5887) (3)
－Teratogenicity study in rabbits－

H.Higuchi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s461-72*

---

Reproductive and developmental toxicity studies of amrubicin hydrochloride (SM-5887) (4)
－Perinatal and postnatal study in rats－

T.Furuhashi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s473-90*

---

Antigenicity study on amrubicin hydrochloride (SM-5887)

T.Nakanishi, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s491-6*

---

Reverse mutation test of amrubicin hydrochloride (SM-5887) in bacterial systems

S.Kogiso, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s497-502*

---

In vitro chromosomal aberration test on amrubicin hydrochloride (SM-5887) in Chinese Hamster ovary cells (CHO-K1)

S.Kogiso, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s503-8*

---

Micronucleus test on amrubicin hydrochloride (SM-5887) in CD-1 mice

M.Hara, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s509-12*

---

Vascular irritation study of amrubicin hydrochloride (SM-5887) in rabbits

A.Matsuda, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s513-20*

---

Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (5)
－Placental transfer and excretion into milk－

S.Nakai, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s521-30*

---

Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (6)
－Pharmacokinetic studies of amrubicinol, the major bioactive metabolite of amurubicin, in rats－

S.Nakai, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s531-43*

---

Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (7)
－Effect of SM-5887 on drug metabolizing enzyme system in rats－

S.Nakai, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s545-50*

---

Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (8)
－Drug-drug interactions of SM-5887 in protein binding－

S.Nakai, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s551-6*

---

Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (9)
－In vivo chiral conversion of SM-5887 and stereoselectivity of reduction of the carbonyl group at the C-13 position－

S.Nakai, et al.

Jpn Pharmacol Ther 1999 27(Suppl.1) s557-68*